Pataer, Apar <br/><br/>
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  May 2012 
 - 825-32 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e318247504a  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--mortality<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--mortality<br/>Carcinoma, Squamous Cell--mortality<br/>Chemotherapy, Adjuvant<br/>Cisplatin--administration & dosage<br/>Combined Modality Therapy<br/>Cross-Sectional Studies<br/>Deoxycytidine--administration & dosage<br/>Etoposide--administration & dosage<br/>Female<br/>Humans<br/>Lung Neoplasms--mortality<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Survival Rate<br/>Gemcitabine